Skip to content

Airway Clearance by Fiberoptic Bronchoscopy in Bronchiectasis Followed by Gentamicin and Dexamethason Injection

The Effect of Intrabronchial Therapy With Gentamycin and Dexamethason After Bronchoscopic Airway Clearance in Exacerbation of Bronchiectasis

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06906354
Enrollment
60
Registered
2025-04-02
Start date
2024-11-11
Completion date
2025-01-20
Last updated
2025-04-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchiectasis Adult, Bronchiectasis With Acute Exacerbation

Keywords

bronchoscopy, bronchiectasis

Brief summary

Fiberoptic Bronchoscopic Removal of Secretions and Antibiotic Injection

Detailed description

fiberoptic bronchoscopic injection of dexamethason and gentamicin after airway clearance

Interventions

PROCEDUREAirway Clearance by Fiberoptic Bronchoscopy in Bronchiectasis Followed by Gentamicin and Dexamethason Injection

Airway Clearance by Fiberoptic Bronchoscopy in Bronchiectasis Followed by Gentamicin and Dexamethason Injection

Sponsors

Alexandria University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE

Intervention model description

Fiberoptic Airway Clearance in Bronchiectasis Exacerbation and Gentamicin-Dexamethason Injection

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

1- Adult subjects. 2- Male and female subjects are enrolled. 3- patients with NCFB confirmed by chest high-resolution computed tomography (HRCT) 4- patients needing antibiotic treatment at the hospital due to exacerbation 5- Patients who underwent AC by bronchoscopy at the hospital. \-

Exclusion criteria

1- Uncooperative subjects. 2- Unwilling to participate. 3- Inability to lie on the back with raised arms over the head for HRCT. 4- Presence of cystic pulmonary fibrosis; 5- Patients with active pulmonary tuberculosis; 6- Those awaiting surgery; 7- Patients who underwent interventional therapy for hemoptysis; those with allergic bronchopulmonary aspergillosis (ABPA); 8- Patients who did not undergo bronchoscopy for different reasons or combined with lung cancer. \-

Design outcomes

Primary

MeasureTime frameDescription
Dyspnea Borg Scaleone monthimprovement in the scale of dyspnea before and after the procedure

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026